A venture capital firm is focused on investing in breakthrough technologies that aim to prevent disease and extend healthspan and lifespan. The firm’s investment sweet spot is at the Seed stage and the firm may consider Series A opportunities on a case-by-case basis. Typical check sizes are around $1M, with the ability to invest up to $5M. The firm is open to opportunities globally, with a particular focus on Europe and the United States. The firm generally does not lead investment rounds or take board seats but provides active support to portfolio companies.
The firm seeks to invest in genuinely innovative and differentiated therapeutics and digital health opportunities. Within therapeutics, the firm prefers areas outside of oncology, with a focus on novel biological targets. Areas of particular interest include aging-related technologies, especially regenerative or reversal approaches rather than simple lifespan extension. Within digital health, the firm is interested in consumer-facing technologies that improve accessibility to healthcare.
The firm is open to engaging at very early stages, including lab spinouts. The firm does not impose specific requirements on companies or management teams.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment